AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12477446 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation and surgery
Number of subjects: 10000
Study 12477446 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 10000
Study 9501783 — intervention group
Group type: EXPERIMENTAL
Intervention: intra‐umbilical vein injection of saline solution plus oxytocin
Number of subjects: 291
Study 9501783 — intervention group
Group type: EXPERIMENTAL
Intervention: intra‐umbilical vein injection of saline solution alone
Number of subjects: 291
Study 9501783 — intervention group
Group type: COMPARATOR
Intervention: expectant management
Number of subjects: 291
Study 7698575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily for 4 months)
Number of subjects: 44
Study 7698575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 1671875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CDA) at doses of 3 to 10.7 mg/m2/d, given as a continuous 5-day infusion
Number of subjects: 31
Study 6131178 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate breast reconstruction
Number of subjects: 64
Study 6131178 — intervention group
Group type: COMPARATOR
Intervention: Control group (reconstruction offered 12 months later)
Number of subjects: 64
Study 31699716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application used by community health agents (CHAs) during home visits to improve child-rearing practices and child health indicators.
Number of subjects: 0
Study 31699716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application used by CHAs.
Number of subjects: 0
Study 31699716 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 28151802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU) - 1 dose
Number of subjects: 0
Study 28151802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU) - 2 doses
Number of subjects: 0
Study 28151802 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU) - 3 doses
Number of subjects: 0
Study 28151802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no doses of erythropoietin)
Number of subjects: 0
Study 26637964 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous, online, 15-week weight loss program
Number of subjects: 80
Study 26637964 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 80
Study 25038914 — intervention group
Group type: EXPERIMENTAL
Intervention: Moviprep®
Number of subjects: 266
Study 25038914 — intervention group
Group type: COMPARATOR
Intervention: Phosphoral®
Number of subjects: 266
Study 23030579 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention including medication reconciliation, inpatient counseling, simple adherence aids, and telephone follow‐up
Number of subjects: 125
Study 20520621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (on-demand for 12 weeks)
Number of subjects: 346
Study 20520621 — intervention group
Group type: COMPARATOR
Intervention: Saffron (30 mg twice daily for 12 weeks)
Number of subjects: 346
Study 18939513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 93
Study 18939513 — intervention group
Group type: COMPARATOR
Intervention: No amnioinfusion (Control)
Number of subjects: 93
Study 16396651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% timolol hydrogel
Number of subjects: 24
Study 16396651 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol aqueous solution
Number of subjects: 24
Study 12562339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,450-nm diode laser (SmoothBeam; Candela Corp., Wayland, MA)
Number of subjects: 25
Study 12562339 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated symmetrical matched areas)
Number of subjects: 25
Study 10190759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline tablet formulation made in China (test tablet)
Number of subjects: 12
Study 10190759 — intervention group
Group type: COMPARATOR
Intervention: Sertraline tablet formulation made in England (reference tablet)
Number of subjects: 12
Study 8027273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction using a luteinizing hormone-releasing hormone agonist plus human menopausal gonadotrophin
Number of subjects: 0
Study 8027273 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous cycles
Number of subjects: 0
Study 2574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 100 mg bid for 2 weeks
Number of subjects: 0
Study 2574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg bid for 2 weeks
Number of subjects: 0
Study 2574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg bid for 2 weeks
Number of subjects: 0
Study 2574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol once-a-day dosing (same total daily dose as prior 2 weeks)
Number of subjects: 0
Study 2574729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (all doses)
Number of subjects: 0
Study 2574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (in 15 patients)
Number of subjects: 0
Study 7342 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐adrenoceptor antagonists
Number of subjects: 25
Study 31885153 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol-binding protein 4 (RBP4)
Number of subjects: 73
Study 31885153 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-8
Number of subjects: 73
Study 31885153 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-18
Number of subjects: 73
Study 31885153 — intervention group
Group type: EXPERIMENTAL
Intervention: CXC chemokine ligand 10 (CXCL10)
Number of subjects: 73
Study 31885153 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP4
Number of subjects: 73
Study 31621256 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Jiaji (EX-B 2), once a day for 10 days, needles retained for 30 min.
Number of subjects: 118
Study 31621256 — intervention group
Group type: COMPARATOR
Intervention: Control group received mosapride citrate (5 mg, 3 times a day), bifidobacterium triple viable capsules (420 mg, twice a day), omeprazole (40 mg, twice a day), and antibiotics.
Number of subjects: 118
Study 28490941 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis combined with conventional behavior management techniques
Number of subjects: 0
Study 28490941 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional behavior management techniques only)
Number of subjects: 0
Study 25742762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (PDE-5 inhibitor)
Number of subjects: 208
Study 23817699 — intervention group
Group type: EXPERIMENTAL
Intervention: salsalate, 3.5 g/d
Number of subjects: 286
Study 23817699 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 286
Study 20215537 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus gefitinib
Number of subjects: 93
Study 20215537 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole plus placebo
Number of subjects: 93
Study 18294741 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59™-adjuvanted vaccine
Number of subjects: 0
Study 18294741 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine
Number of subjects: 0
Study 16754711 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (40 mg loading, 7.5 mg maintenance, n = 1)
Number of subjects: 9
Study 16754711 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading, 10 mg maintenance, n = 4)
Number of subjects: 9
Study 16754711 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading, 15 mg maintenance, n = 2)
Number of subjects: 9
Study 16754711 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading, 75 mg maintenance, n = 2)
Number of subjects: 9
Study 16754711 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg daily, n = 2)
Number of subjects: 9
Study 12789875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall-focused pharmaceutical intervention program (FFPIP)
Number of subjects: 200
Study 10641431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions (difficulty level not specified)
Number of subjects: 146
Study 10641431 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of spectral analysis studies
Number of subjects: 146
Study 10641431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-study correlations
Number of subjects: 146
Study 8981339 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate (2 mg daily)
Number of subjects: 53
Study 8981339 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (50 micrograms/24 h) transcutaneously
Number of subjects: 53
Study 8981339 — intervention group
Group type: COMPARATOR
Intervention: No substitution
Number of subjects: 53
Study 1607498 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy (PE)
Number of subjects: 26
Study 1607498 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 26
Study 3928313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxim (Claforan)
Number of subjects: 764
Study 3928313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 764
Study 31441999 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil
Number of subjects: 13
Study 31441999 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (benchmark)
Number of subjects: 13
Study 29655627 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200 (derived from the CVD 103‐HgR strain)
Number of subjects: 0
Study 27314013 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Virtual Template Group (DVTG)
Number of subjects: 23
Study 27314013 — intervention group
Group type: COMPARATOR
Intervention: Hand-Free Group (HFG)
Number of subjects: 23
Study 24875033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicruciate substituting knee system
Number of subjects: 124
Study 24875033 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterior stabilized system
Number of subjects: 124
Study 22732098 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually prescribed cognitive behavior therapy text modules with online therapist guidance
Number of subjects: 57
Study 22732098 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 57
Study 20657090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice
Number of subjects: 42
Study 20657090 — intervention group
Group type: COMPARATOR
Intervention: No Dentifrice (Control)
Number of subjects: 42
Study 18596312 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg IV every 6 hours
Number of subjects: 20
Study 18596312 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg IV every 6 hours
Number of subjects: 20
Study 16018840 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 301
Study 16018840 — intervention group
Group type: COMPARATOR
Intervention: No revascularization
Number of subjects: 301
Study 12449696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study 10049657 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 43
Study 10049657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 43
Study 10049657 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 43
Study 8523926 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of desmopressin acetate (DDAVP) at a dosage of 0.3 micrograms/kg, 35 minutes prior to plasmapheresis.
Number of subjects: 15
Study 8523926 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 15
Study 1838424 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 192,605 (100 mg orally)
Number of subjects: 16
Study 1838424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6957991 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Pirenzepine daily
Number of subjects: 126
Study 6957991 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg Cimetidine daily
Number of subjects: 126
Study 31322918 — intervention group
Group type: EXPERIMENTAL
Intervention: All-suture anchors
Number of subjects: 16
Study 31322918 — intervention group
Group type: COMPARATOR
Intervention: Titanium suture anchors
Number of subjects: 16
Study 29076259 — intervention group
Group type: EXPERIMENTAL
Intervention: Health halo condition (unfamiliar nutrient-poor food/drink ads with healthy messages)
Number of subjects: 138
Study 29076259 — intervention group
Group type: COMPARATOR
Intervention: Nutrient-poor food/drink ads with other messages
Number of subjects: 138
Study 29076259 — intervention group
Group type: COMPARATOR
Intervention: Healthy food/drink ads
Number of subjects: 138
Study 26869586 — intervention group
Group type: EXPERIMENTAL
Intervention: TC + BRx
Number of subjects: 21
Study 26869586 — intervention group
Group type: COMPARATOR
Intervention: TC + water
Number of subjects: 21
Study 26869586 — intervention group
Group type: COMPARATOR
Intervention: BRx
Number of subjects: 21
Study 26869586 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 21
Study 24852584 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bottled water
Number of subjects: 48
Study 24852584 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (maximum 2 L over 2 hours)
Number of subjects: 48
Study 21342170 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% nadifloxacin cream
Number of subjects: 0
Study 21342170 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study 19696604 — intervention group
Group type: EXPERIMENTAL
Intervention: Home healthcare (three home visits with evidence-based nursing care)
Number of subjects: 42
Study 19696604 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pain control and management through the pain clinic)
Number of subjects: 42
Study 17097761 — intervention group
Group type: EXPERIMENTAL
Intervention: Caralluma extract (1 g per day for 60 days)
Number of subjects: 50
Study 17097761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15563389 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 319
Study 15563389 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 319
Study 11451781 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 47088
Study 11451781 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores of 10, 20, 30, 40, 50, and 60
Number of subjects: 47088
Study 11451781 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction models
Number of subjects: 47088
Study 9559735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 303
Study 8022537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin as add-on therapy
Number of subjects: 3
Study 8022537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 3363025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 64
Study 3363025 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 64
Study 3363025 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 64
Study 29353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Number of subjects: 40
Study 29353388 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomic landmark palpation guidance injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Number of subjects: 40
Study 29353388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 40
Study 29353388 — intervention group
Group type: COMPARATOR
Intervention: Conventional anatomic landmark palpation guidance injection
Number of subjects: 40
Study 26861113 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES) with paclitaxel
Number of subjects: 137
Study 26861113 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty plus Bail-out Bare Metal Stenting (PTA±BMS)
Number of subjects: 137
Study 26861113 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 137
Study 25250712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thalamic deep brain stimulation (DBS)
Number of subjects: 5
Study 24354627 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAQ
Number of subjects: 534
Study 24354627 — intervention group
Group type: COMPARATOR
Intervention: AL
Number of subjects: 534
Study 24354627 — intervention group
Group type: COMPARATOR
Intervention: DHAPQ
Number of subjects: 534
Study 24354627 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 534
Study 20722814 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental educational intervention (bookmark, booklet on pain management, and pain scale)
Number of subjects: 195
Study 20722814 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received a pain scale)
Number of subjects: 195
Study 20722814 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental educational intervention
Number of subjects: 195
Study 20722814 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 18081735 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life questionnaires (EORTC QLQ C-30 and QLQ OES18)
Number of subjects: 96
Study 18081735 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life questionnaires (specific scales: physical functioning, fatigue, and reflux)
Number of subjects: 96
Study 16959672 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CI therapy) for subacute therapy group (3 to 9 months after stroke)
Number of subjects: 32
Study 16959672 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CI therapy) for chronic therapy group (1 year after stroke)
Number of subjects: 32
Study 16959672 — intervention group
Group type: COMPARATOR
Intervention: Comparison of subacute and chronic therapy groups
Number of subjects: 32
Study 14594455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing lutein, vitamins A, C and E, zinc, and copper
Number of subjects: 0
Study 14594455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10671945 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I 50 microg/kg subcutaneously thrice daily during a six day study period
Number of subjects: 8
Study 10671945 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I treatment
Number of subjects: 8
Study 10671945 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 8
Study 9190048 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit memory test using picture fragments; explicit memory test with yes/no recognition.
Number of subjects: 0
Study 1341893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium tosylate (5 mg/kg every 6 hours for 48-72 hours)
Number of subjects: 63
Study 1341893 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (control group)
Number of subjects: 63
Study 1341893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium tosylate
Number of subjects: 63
Study 3897961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) 20 mg/kg, two intravenous injections
Number of subjects: 181
Study 3897961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 3897961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX)
Number of subjects: 181
Study 30867079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AT) for 6 months
Number of subjects: 0
Study 30867079 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control [CON]) for 6 months
Number of subjects: 0
Study 29411314 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling exercise (TCE) intervention
Number of subjects: 51
Study 29411314 — intervention group
Group type: COMPARATOR
Intervention: Self-directed exercise (SDE) group
Number of subjects: 51
Study 27349219 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro
Number of subjects: 0
Study 27349219 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 25277334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 485
Study 22155755 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6
Number of subjects: 60
Study 22155755 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab every 8 weeks (q8w)
Number of subjects: 60
Study 22155755 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab every 12 weeks (q12w)
Number of subjects: 60
Study 22155755 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall remission rate
Number of subjects: 60
Study 20227541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol administration intervals between 0 and 72 hours
Number of subjects: 5139
Study 20227541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol administration intervals less than 8 hours
Number of subjects: 5139
Study 20227541 — intervention group
Group type: COMPARATOR
Intervention: Longer administration intervals (greater than 8 hours)
Number of subjects: 5139
Study 18090070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg bolus, followed by 4 microg/kg/min infusion)
Number of subjects: 34
Study 18090070 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline, equal volume)
Number of subjects: 34
Study 15145973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib (400 mg daily)
Number of subjects: 0
Study 15145973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11920261 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional first-line chemotherapy (ACVBP)
Number of subjects: 810